Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Sarcoma 12Lymphoma, Large B-Cell, Diffuse 12Sarcoma, Ewing 4Lymphoma, B-Cell 4Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Osteosarcoma 3Neurofibrosarcoma 3Lymphoma, Non-Hodgkin 3Liposarcoma 3Hodgkin Disease 3Fibrosarcoma 3Sarcoma, Synovial 2Sarcoma, Clear Cell 2Rhabdomyosarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 2Nerve Sheath Neoplasms 2Neoplasms, Germ Cell and Embryonal 2Lymphoma, Follicular 2Lymphoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Histiocytoma, Angiomatoid Fibrous 2Hemangiosarcoma 2Granuloma, Plasma Cell 2Desmoplastic Small Round Cell Tumor 2Dermatofibrosarcoma 2Chondrosarcoma, Extraskeletal Myxoid 2Burkitt Lymphoma 2

Interventions

Cyclophosphamide 47Rituximab 31fludarabine 29Specimen Handling 13Magnetic Resonance Spectroscopy 13Doxorubicin 13pirtobrutinib 11Vincristine 11Prednisone 11fludarabine phosphate 10Immunotherapy, Adoptive 10Etoposide 10Bendamustine Hydrochloride 10obinutuzumab 8Lenalidomide 8Biopsy 8venetoclax 7polatuzumab vedotin 7glofitamab 7zanubrutinib 6pembrolizumab 6Dexamethasone 6tafasitamab 5ibrutinib 5etoposide phosphate 5acalabrutinib 5Leukapheresis 5tazemetostat 4loncastuximab tesirine 4Nivolumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × Ifosfamide × 1 year × Clear all
NCT06230224 2026-05-11

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
216 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT05991388 2026-02-20

Glo-BNHL

University of Birmingham

Phase 2/3 Recruiting
210 enrolled
Lymphoid

Lymphoma, B-Cell

NCT05821088 2025-11-20

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
37 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07081022 2025-08-21

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
180 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡